Literature DB >> 35450356

New Highly Potent NLRP3 Inhibitors: Furanochalcone Velutone F Analogues.

Ruijia Zhang1, Feng Hong1, Min Zhao2, Xiaoying Cai1, Xueqin Jiang1, Neng Ye1, Kaiyue Su1, Na Li1, Minghai Tang1, Xu Ma1, Hengfan Ni3, Lun Wang1, Li Wan3, Lijuan Chen1, Wenshuang Wu4,5, Haoyu Ye1.   

Abstract

The NLRP3 inflammasome has now emerged as one of the most appealing drug targets for many inflammation-related diseases. Velutone F, a natural NLPR3 inhibitor, identified in our previous study has been limited in application by its low in planta abundance, weak activity, and complicated synthetic routes. To address these needs, structural optimization of velutone F led to a series of novel NLRP3 inhibitors. Among them, compound 14c exerted remarkable inhibitory activity with an IC50 value in the nanomolar range (251.1 nM) and was approximately 5-fold more potent than velutone F. Moreover, the synthesis method of 14c was simple, easy to handle, and scalable. Compound 14c could suppress NLRP3 inflammasome activation by attenuating ASC speck formation. Most importantly, compound 14c reduced peritoneal neutrophil influx in mice and IL-1β in the spleen in the MSU-induced peritonitis in LPS-primed mouse model. Taken together, compound 14c is a prospective lead compound in the discovery of NLRP3 inflammasome inhibitors.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35450356      PMCID: PMC9014504          DOI: 10.1021/acsmedchemlett.1c00597

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  38 in total

1.  Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency.

Authors:  P Boyle; C Diehm; C Robertson
Journal:  Int Angiol       Date:  2003-09       Impact factor: 2.789

2.  Target identification using drug affinity responsive target stability (DARTS).

Authors:  Brett Lomenick; Rui Hao; Nao Jonai; Randall M Chin; Mariam Aghajan; Sarah Warburton; Jianing Wang; Raymond P Wu; Fernando Gomez; Joseph A Loo; James A Wohlschlegel; Thomas M Vondriska; Jerry Pelletier; Harvey R Herschman; Jon Clardy; Catherine F Clarke; Jing Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

3.  Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.

Authors:  Cheng Zhang; Hu Yue; Ping Sun; Lei Hua; Shuli Liang; Yitao Ou; Dan Wu; Xinyi Wu; Hao Chen; Ying Hao; Wenhui Hu; Zhongjin Yang
Journal:  Eur J Med Chem       Date:  2021-04-01       Impact factor: 6.514

Review 4.  Beneficial Properties of Phytochemicals on NLRP3 Inflammasome-Mediated Gout and Complication.

Authors:  Jhih-Jia Jhang; Jia-Hong Lin; Gow-Chin Yen
Journal:  J Agric Food Chem       Date:  2018-01-17       Impact factor: 5.279

5.  Chalcone derivatives bearing chromen or benzo[f]chromen moieties: Design, synthesis, and evaluations of anti-inflammatory, analgesic, selective COX-2 inhibitory activities.

Authors:  Zhi-Yang Fu; Qing-Hao Jin; Yu-Le Qu; Li-Ping Guan
Journal:  Bioorg Med Chem Lett       Date:  2019-05-28       Impact factor: 2.823

6.  Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease.

Authors:  Mattia Cocco; Carolina Pellegrini; Helios Martínez-Banaclocha; Marta Giorgis; Elisabetta Marini; Annalisa Costale; Gianluca Miglio; Matteo Fornai; Luca Antonioli; Gloria López-Castejón; Ana Tapia-Abellán; Diego Angosto; Iva Hafner-Bratkovič; Luca Regazzoni; Corrado Blandizzi; Pablo Pelegrín; Massimo Bertinaria
Journal:  J Med Chem       Date:  2017-04-24       Impact factor: 7.446

7.  Effective treatment for sensitive skin: 4-t-butylcyclohexanol and licochalcone A.

Authors:  M Sulzberger; A-C Worthmann; U Holtzmann; B Buck; K A Jung; A M Schoelermann; F Rippke; F Stäb; H Wenck; G Neufang; E Grönniger
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-02       Impact factor: 6.166

8.  Randomized investigator-blinded comparative study of moisturizer containing 4-t-butylcyclohexanol and licochalcone A versus 0.02% triamcinolone acetonide cream in facial dermatitis.

Authors:  Waranya Boonchai; Supenya Varothai; Waranaree Winayanuwattikun; Sutasinee Phaitoonvatanakij; Pichanee Chaweekulrat; Pranee Kasemsarn
Journal:  J Cosmet Dermatol       Date:  2018-02-06       Impact factor: 2.696

9.  Inflammasome Assays In Vitro and in Mouse Models.

Authors:  Haitao Guo; Jenny P-Y Ting
Journal:  Curr Protoc Immunol       Date:  2020-12

10.  Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors.

Authors:  Weiyang Dai; Soma Samanta; Ding Xue; Elyse M Petrunak; Jeanne A Stuckey; Yanyan Han; Duxin Sun; Yong Wu; Nouri Neamati
Journal:  J Med Chem       Date:  2019-02-22       Impact factor: 7.446

View more
  1 in total

1.  Synthesis and NLRP3-Inflammasome Inhibitory Activity of the Naturally Occurring Velutone F and of Its Non-Natural Regioisomeric Chalconoids.

Authors:  Tiziano De Ventura; Mariasole Perrone; Sonia Missiroli; Paolo Pinton; Paolo Marchetti; Giovanni Strazzabosco; Giulia Turrin; Davide Illuminati; Virginia Cristofori; Anna Fantinati; Martina Fabbri; Carlotta Giorgi; Claudio Trapella; Vinicio Zanirato
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.